Platelet transfusion; concentrates from single or from multiple donors?;Transfusión de plaquetas, ¿concentrados procedentes de un único o de múltiples donantes?

Medicina Clinica

Volumn 122, Issue 4, 2004, Pages 145-149

  Lozano, María Luisa ^a   Vicente, Vicente ^a  

^a HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

ALLOIMMUNIZATION; BLOOD DONOR; BLOOD TRANSFUSION REACTION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEMOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; REVIEW; THROMBOCYTE TRANSFUSION; VIRUS TRANSMISSION;

EID: 1642285892     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(04)74175-5     Document Type: Review

References (25)

1. Böck M, Rahrig S, Kunz D, Lutze G, Heim MU. Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences. Transfus Med 2002;12:317-24.
2. Kocazeybek B, Arabaci U, Akdur H, Sezgic M, Erenturk S. Prospective evaluation of platelets prepared by single and random methods during 5 days of storage: aspects related to quality and quantity. Transfus Apheresis Sci 2002;26:29-34.
3. Turner VS, Hawker RJ, Mitchell SG, Seymour Mead AM. Paired in vivo and in vitro comparison of apheresis and 'recovered' platelet concentrates stored for 5 days. J Clin Apheresis 1994;9:189-94.
4. Algora Weber M, Fernandez Montoya A, Gómez Villagran JL, Mart Vega C, Prats Arrojo I, Puig Alcaraz N, et al. Guía sobre la indicación de la transfusión de glóbulos rojos, plaquetas y productos plasmáticos lábiles. Med Clin (Barc) 1999;113:471-4.
5. Eriksson L, Kristensen J, Olsson K, Bring J, Hogman CF. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coats and apheresis. Vox Sang 1996;70: 69-75.
6. Strindberg J, Berlin G. Transfusion of platelet concentrates - clinical evaluation of two preparations. Eur J Haematol 1996;57:307-11.
7. Kluter H, Dorges L, Maass E, Wagner T, Bartels H, Kirchner H. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. Ann Hematol 1996;73:85-9.
8. Kelley DL, Fegan RL, Ng AT, Kennedy MK, Blanda E, Chambers LA, et al. High-yield platelet concentrates attainable by continuous quality improvement reduce platelet transfusion cost and donor exposure. Transfusion 1997;37:482-6.
9. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet Transfusions. N Engl J Med 1997; 37:1861-9.
10. Sarkodee-Adoo CB, Kendall JM, Sridhara R, Lee EJ, Schiffer CA. The relationship between the duration of platelet storage and the development of transfusion reactions. Transfusion 1998;38:229-35.
11. Ferrer F, Rivera J, Corral J, González-Conejero R, Lozano ML, Vicente V. Evaluation of pooled platelet concentrates using prestorage versus postorage WBC reduction: impact of filtration timing. Transfusion 2000;40: 781-8.
12. Sweeney JD, Holme S, Heaton WAL, Nelson E. Leukodepleted platelet concentrates prepared by in filtration of platelet rich plasma. Transfusion 1995;35:131-6.
13. Anderson NA, Gray S, Copplestone JA, Chan DC, Hamon M, Prentice AG, et al. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfus Med 1997;7:33-9.
14. Chalandon Y, Mermillod B, Beris P, Doucet A, Chapuis B, Roux-Lombard P, et al. Benefit of prestorage leukocyte depletion of single-donor platelet concentrates. Vox Sang 1999;76:27-37.
15. Pérez P, Salmi R, Folléa G, Schmit JL, De Barbeyrac B, Sudre P, et al. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM case-control study. Transfusion 2001;41:862-72.
16. Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, Schreiber GB, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001;41:1493-9.
17. Ness PM, Braine HG, King KE, Barrasso C, Kennedy SD. Single donor platelets reduce the risk of septic transfusion reactions [abstract]. Transfusion 1999;39:S404A.
18. Álvarez M, Oyonarte S, Rodríguez PM, Hernández JM. Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion 2002;42: 994-8.
19. McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, et al. Frequency of immediate adverse events associated with apheresis donation. Transfusion 1998;38:938-43.
20. Popovsky MA, Whitaker B, Arnold NL. Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. Transfusion 1995;35:734-7.
21. Despotis GJ, Goodnough LT, Dynis M, Baorto D, Spitznagel E. Adverse events in platelet apheresis donors: a multivariate analysis in a hospital-based program. Vox Sang 1999;77:24-32.
22. Sweeney JD, Petrucci J, Yankee R. Pooled platelet concentrates: maybe not fancy, but fiscally sound and effective. Trans Sci 1997;18:575-83.
23. López-Plaza I, Weissfeld J, Triulzi DJ. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 1999;39:925-32.
24. AuBuchon JP. Lessons learned from decision analysis. Transfusion 1996;36:755-60.
25. Blumberg N, Heal JM. Mortality risks, costs, and decision making in transfusion medicine. Am J Clin Pathol 2000;114:934-7.